IVX.AX - Invion Limited
Invion Limited
100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9692 7222
https://www.inviongroup.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Thian Chew | Exec. Chairman & CEO | 583.87k | N/A | N/A |
| Ms. Melanie Jaye Leydin B.Bus, C.A., CA | Chief Financial Officer | N/A | N/A | 1973 |
| Dr. Dean Naylor | Head of Intellectual Property Devel. | N/A | N/A | N/A |
| Ms. Claire Newstead-Sinclair BBus, C.A., CA | Company Sec. | N/A | N/A | N/A |
Description
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Corporate governance
Invion Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
